Study of RP-6306 With Gemcitabine in Advanced Solid Tumors

Status Active, not recruiting

Clinical Trial Summary

The primary purpose of this study is to assess the safety and tolerability of RP-6306 in combination gemcitabine, in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-6306 in combination with gemcitabine, identify a recommended phase 2 dose (RP2D) and preferred schedule, examine preliminary pharmacokinetics (PK) and assess anti-tumor activity.

Clinical Trial Description

Phase 1, multi-center, open-label, dose-escalation study to: - Evaluate the safety profile and MTD of RP-6306 with gemcitabine to establish the RP2D and schedule - Characterize the PK and pharmacodynamics of RP-6306 with gemcitabine - Assess preliminary anti-tumor activity associated with RP-6306 with gemcitabine ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05147272
Study type	Interventional
Source	Repare Therapeutics
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	December 16, 2021
Completion date	April 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06059547` - Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer	Phase 2
Active, not recruiting	`NCT04538625` - Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy	Phase 3
Completed	`NCT01037790` - Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer	Phase 2
Recruiting	`NCT06403436` - A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors	Phase 1
Recruiting	`NCT03061305` - Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
Active, not recruiting	`NCT02568267` - Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)	Phase 2
Terminated	`NCT05357898` - Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Not yet recruiting	`NCT06277804` - A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor	Phase 1
Completed	`NCT03818347` - Hydrogen Gas for Cancer Rehabilitation	N/A
Completed	`NCT05400265` - Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor	Phase 1
Recruiting	`NCT04705818` - Combining Epigenetic And Immune Therapy to Beat Cancer.	Phase 2
Completed	`NCT01269918` - A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain	N/A
Suspended	`NCT03253575` - CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
Completed	`NCT04084951` - Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors	Phase 1
Completed	`NCT03760952` - Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
Active, not recruiting	`NCT03445858` - Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults	Early Phase 1
Completed	`NCT03303365` - Cyberknife Radiosurgery for Patients With Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence	N/A
Not yet recruiting	`NCT05666635` - Study of LTC004 in Subjects With Advanced Malignant Tumors	Phase 1
Recruiting	`NCT05752552` - Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours	Phase 1
Terminated	`NCT04892043` - Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors	Phase 1